Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 2, 2008, Pages 305-313

  Aissat, Nasredine ^a   Le Tourneau, Christophe ^a   Ghoul, Aïda ^a   Serova, Maria ^a   Bieche, Ivan ^a   Lokiec, François ^b   Raymond, Eric ^a   Faivre, Sandrine ^a  

^a BEAUJON HOSPITAL   (France)

^b CENTRE RENÉ HUGUENIN   (France)

Author keywords

Apoptosis; Cytotoxicity; mTOR; PI3K AKT pathway

Indexed keywords

BCL2 RELATED PROTEIN A1; CARBOPLATIN; CYCLIN D1; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN NOXA; RAPAMYCIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 43749116022     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0609-2     Document Type: Article

References (33)

1. 1. JR Grandis DJ Tweardy 1993 Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer Cancer Res 53 3579 3584 8339264 1:CAS:528:DyaK3sXmtVSrsbo%3D Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579–3584
2. 2. JR Grandis MF Melhem WE Gooding 1998 Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival J Natl Cancer Inst 90 824 832 10.1093/jnci/90.11.824 Grandis JR, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824–832
3. 3. I Vivanco CL Sawyers 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 489 501 12094235 10.1038/nrc839 1:CAS:528:DC%2BD38XkvFKltLs%3D Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501
4. 4. EJ Brown MW Albers TB Shin 1994 A mammalian protein targeted by G1-arrestingreceptor complex Nature 369 756 768 8008069 10.1038/369756a0 1:CAS:528:DyaK2cXlsFSiu74%3D Brown EJ, Albers MW, Shin TB et al (1994) A mammalian protein targeted by G1-arrestingreceptor complex. Nature 369:756–768
5. 5. MA Bjornsti PJ Houghton 2004 The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 335 348 15122205 10.1038/nrc1362 1:CAS:528:DC%2BD2cXjsFSlu7Y%3D Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–348
6. 6. S Vignot S Faivre D Aguirre 2005 mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 525 537 15728109 10.1093/annonc/mdi113 1:STN:280:DC%2BD2M7kvVWmsQ%3D%3D Vignot S, Faivre S, Aguirre D et al (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525–537
7. 7. MA Bjornsti PJ Houghton 2004 Lost in translation: dysregulation of cap-dependent translation and cancer Cancer Cell 5 519 523 15193254 10.1016/j.ccr.2004.05.027 1:CAS:528:DC%2BD2cXltlGgs7g%3D Bjornsti MA, Houghton PJ (2004) Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 5:519–523
8. 8. JF Gera IK Mellinghoff Y Shi 2004 AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression J Biol Chem 4 2737 2746 Gera JF, Mellinghoff IK, Shi Y et al (2004) AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 4:2737–2746
9. 9. S Faivre G Kroemer E Raymond 2006 Current development of mTOR inhibitors as anticancer agents Nat Rev Drug Discov 5 8 671 688 16883305 10.1038/nrd2062 1:CAS:528:DC%2BD28XnsFCkurk%3D Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5(8):671–688
10. 10. M Grewe F Gansauge RM Schmid 1999 Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells Cancer Res 59 3581 3587 10446965 1:CAS:528:DyaK1MXltFCgur8%3D Grewe M, Gansauge F, Schmid RM et al (1999) Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 59:3581–3587
11. 11. J Dong J Peng H Zhang 2005 Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity Cancer Res 65 5 1961 1972 15753396 10.1158/0008-5472.CAN-04-2501 1:CAS:528:DC%2BD2MXitVOjt70%3D Dong J, Peng J, Zhang H et al (2005) Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 65(5):1961–1972
12. 12. E Oki H Baba E Tokunaga 2005 Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer Int J Cancer 117 3 376 380 15900596 10.1002/ijc.21170 1:CAS:528:DC%2BD2MXhtFant7rJ Oki E, Baba H, Tokunaga E et al (2005) Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 117(3):376–380
13. 13. B Geoerger K Kerr CB Tang 2001 Antitumor activity of the Rapamycin analog CCI-779 in human primitive neuroectodermal Tumor/Medulloblastoma models as single agent and in combination Chemotherapy Cancer Res 61 1527 1532 11245461 1:CAS:528:DC%2BD3MXhvVeltb8%3D Geoerger B, Kerr K, Tang CB et al (2001) Antitumor activity of the Rapamycin analog CCI-779 in human primitive neuroectodermal Tumor/Medulloblastoma models as single agent and in combination Chemotherapy. Cancer Res 61:1527–1532
14. 14. A Gupta Y Dai RR Vethanayagam 2006 Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan Cancer Chemother Pharmacol 58 3 374 383 16404634 10.1007/s00280-005-0173-6 1:CAS:528:DC%2BD28XkvFOisr0%3D Gupta A, Dai Y, Vethanayagam RR et al (2006) Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58(3):374–383
15. 15. I Nagasawa P Keng C Maki 1988 Absence of a radiation-induced first-cycle G 1-S arrest in p53+ human tumor cells synchronized by mitotic selection Cancer Res 58 2036 2041 Nagasawa I, Keng P, Maki C et al (1988) Absence of a radiation-induced first-cycle G 1-S arrest in p53+ human tumor cells synchronized by mitotic selection. Cancer Res 58:2036–2041
16. 16. L Maggiorella V Frascogna MG Poullain 2001 The Olivacine S16020 enhances the Antitumor effect of ionizing radiation without increasing radio-induced Mucositis Clin Cancer Res 7 2091 2095 11448928 1:CAS:528:DC%2BD3MXlslalu7Y%3D Maggiorella L, Frascogna V, Poullain MG et al (2001) The Olivacine S16020 enhances the Antitumor effect of ionizing radiation without increasing radio-induced Mucositis. Clin Cancer Res 7:2091–2095
17. 17. DG Brachman M Beckett D Graves 1993 p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines Cancer Res 53 3667 3669 8339273 1:CAS:528:DyaK3sXmsVCmsbc%3D Brachman DG, Beckett M, Graves D et al (1993) p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 53:3667–3669
18. 18. I Bièche B Parfait S Tozlu 2001 Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene Carcinogenesis 22 1521 1526 11532875 10.1093/carcin/22.9.1521 Bièche I, Parfait B, Tozlu S et al (2001) Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. Carcinogenesis 22:1521–1526
19. 19. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 6382953 10.1016/0065-2571(84)90007-4 1:CAS:528:DyaL2cXktlaksLk%3D Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55
20. 20. A Janus T Robak P Smolewski 2005 The mammalian target of rapamycin (mTOR) kinase pathway. It’s role in tumourgenesis and targeted antitumour therapy Cell Mol Biol Lett 10 479 498 16217558 1:CAS:528:DC%2BD2MXht1ehsrrJ Janus A, Robak T, Smolewski P (2005) The mammalian target of rapamycin (mTOR) kinase pathway. It’s role in tumourgenesis and targeted antitumour therapy. Cell Mol Biol Lett 10:479–498
21. 21. GJ Wiederrecht CJ Sabers GJ Brunn 1995 Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells Prog Cell Cycle Res 1 53 71 9552353 1:CAS:528:DyaK28Xkt1Kgu70%3D Wiederrecht GJ, Sabers CJ, Brunn GJ et al (1995) Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res 1:53–71
22. 22. MS Neshat IK Mellinghoff C Tran 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci USA 98 10314 10319 11504908 10.1073/pnas.171076798 1:CAS:528:DC%2BD3MXmvFWiurk%3D Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319
23. 23. W Mondesire W Jian H Zhang 2004 Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells Clin Cancer Res 10 7031 7042 15501983 10.1158/1078-0432.CCR-04-0361 1:CAS:528:DC%2BD2cXpslGlurY%3D Mondesire W, Jian W, Zhang H et al (2004) Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10:7031–7042
24. 24. H Harada J Andersen M Mann 2001 p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD Porc Natl Acad Sci USA 98 9666 9670 10.1073/pnas.171301998 1:CAS:528:DC%2BD3MXmtlCnu7o%3D Harada H, Andersen J, Mann M et al (2001) p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Porc Natl Acad Sci USA 98:9666–9670
25. 25. X Le W Hittelman J Liu 2003 Paclitaxel induces inactivation of p70S6 kinase and phosphorylation of The 421 and Ser 424 via multiple signaling pathways in mitosis Oncogene 22 484 497 12555062 10.1038/sj.onc.1206175 1:CAS:528:DC%2BD3sXmslGksw%3D%3D Le X, Hittelman W, Liu J et al (2003) Paclitaxel induces inactivation of p70S6 kinase and phosphorylation of The 421 and Ser 424 via multiple signaling pathways in mitosis. Oncogene 22:484–497
26. 26. X Wan L Helman 2002 Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70S6 kinase pathway Neoplasia 4 400 408 12192598 10.1038/sj.neo.7900242 1:CAS:528:DC%2BD38XmtlWlurk%3D Wan X, Helman L (2002) Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70S6 kinase pathway. Neoplasia 4:400–408
27. 27. K Yamamoto H Ichijo S Korsmeyer 1999 BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-Terminal protein kinase pathway normally activated at G2/M Mol Cell Biol 19 8469 8478 10567572 1:CAS:528:DyaK1MXns1yguro%3D Yamamoto K, Ichijo H, Korsmeyer S (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-Terminal protein kinase pathway normally activated at G2/M. Mol Cell Biol 19:8469–8478
28. 28. K Floros H Thomadaki N Katsaros 2004 mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin J Biol Chem 385 1099 1103 10.1515/BC.2004.143 1:CAS:528:DC%2BD2cXhtVGlsb7E Floros K, Thomadaki H, Katsaros N et al (2004) mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. J Biol Chem 385:1099–1103
29. 29. E Raymond J Alexandre S Faivre 2002 Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction J Clin Oncol 20 4303 4012 12409328 10.1200/JCO.2002.03.123 1:CAS:528:DC%2BD38Xpt1CjtLg%3D Raymond E, Alexandre J, Faivre S et al (2002) Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 20:4303–4012
30. 30. MJ Ratain KL Napoli K Knightley Moshier 2007 A phase 1b study of oral rapamycin (sirolimus) in patients with advanced malignancies J Clin Oncol 25 3510 Ratain MJ, Napoli KL, Knightley Moshier K et al (2007) A phase 1b study of oral rapamycin (sirolimus) in patients with advanced malignancies. J Clin Oncol 25:3510
31. 31. D Aguirre P Boya D Bellet 2004 Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma Apoptosis 6 797 805 10.1023/B:APPT.0000045781.46314.e2 Aguirre D, Boya P, Bellet D et al (2004) Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 6:797–805
32. 32. W Noh W Mondesire J Peng 2004 Determinants of Rapamycin sensitivity in breast cancer cells Clin Cancer Res 10 1013 1023 14871980 10.1158/1078-0432.CCR-03-0043 1:CAS:528:DC%2BD2cXhtFCgurY%3D Noh W, Mondesire W, Peng J et al (2004) Determinants of Rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013–1023
33. 33. C Wu M Wangpaichitr L Feun 2005 Overcoming cispaltin resistance by mTOR inhibitor in lung cancer Molecular Cancer 4 1 10 10.1186/1476-4598-4-1 Wu C, Wangpaichitr M, Feun L et al (2005) Overcoming cispaltin resistance by mTOR inhibitor in lung cancer. Molecular Cancer 4:1–10